Comorbidities Associated With Residual Cardiovascular Risk in Patients With Chronic Coronary Syndrome Receiving Statin Therapy　― Subanalysis of the REAL-CAD Trial ―-Reference-Cited by-同舟云学术

Comorbidities Associated With Residual Cardiovascular Risk in Patients With Chronic Coronary Syndrome Receiving Statin Therapy　― Subanalysis of the REAL-CAD Trial ―

Published:2022-09-09 Issue:9 Volume:4 Page:422-428
ISSN:2434-0790
Container-title:Circulation Reports
language:en
Short-container-title:Circ Rep

Author:

Wakabayashi Kohei¹,Suzuki Hiroshi²,Fukumoto Yoshihiro³,Obara Hitoshi⁴,Kakuma Tatsuyuki⁴,Sakuma Ichiro⁵,Kimura Takeshi⁶,Iimuro Satoshi⁷,Daida Hiroyuki⁸,Shimokawa Hiroaki⁹,Nagai Ryozo¹⁰

Affiliation:

1. Cardiovascular Center, Showa University Koto-Toyosu Hospital

2. Division of Cardiology, Showa University Fujigaoka Hospital

3. Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine

4. Biostatistics Center, Kurume University

5. Caress Sapporo Hokko Memorial Clinic

6. Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

7. Innovation and Research Support Center, International University of Health and Welfare

8. Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine

9. Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine

10. Jichi Medical University

Publisher

Japanese Circulation Society

Subject

Marketing,Organizational Behavior and Human Resource Management,Strategy and Management,Drug Discovery,Pharmaceutical Science,Pharmacology

Link

https://www.jstage.jst.go.jp/article/circrep/4/9/4_CR-22-0070/_pdf

Reference33 articles.

1. 1. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435.

2. 2. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670–1681.

3. 3. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387–2397.

4. 4. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–1722.

5. 5. Fitchett DH, Leiter LA, Lin P, Pickering J, Welsh R, Stone J, et al. Update to evidence-based secondary prevention strategies after acute coronary syndrome. CJC Open 2020; 2: 402–415.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between Non-Lipid Residual Risk Factors and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Pitavastatin: An Observation from the REAL-CAD Study;Journal of Atherosclerosis and Thrombosis;2024-01-01

2. The Worst Combination for Coronary Artery Disease Under Strong-Statin Therapy Is Chronic Kidney Disease and Diabetes　― Non-Lipid Residual Risk Assessment From the REAL-CAD Study ―;Circulation Journal;2023-10-19

3. Residual Coronary Risk Factors Associated With Long-Term Clinical Outcomes in Patients With Coronary Artery Disease Treated With High- vs. Low-Dose Statin Therapy　― REAL-CAD Substudy ―;Circulation Journal;2023-07-21